Chemoinformaics analysis of Tabernaemontanine
| Molecular Weight | 354.45 | nRot | 2 |
| Heavy Atom Molecular Weight | 328.242 | nRig | 23 |
| Exact Molecular Weight | 354.194 | nRing | 4 |
| Solubility: LogS | -4.145 | nHRing | 2 |
| Solubility: LogP | 3.359 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 52 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 26 | No. of Aromatic Carbocycles | 1 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 2 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 26 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 21 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 9 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 10 |
| nHA | 4 | APOL | 57.0126 |
| nHD | 1 | BPOL | 31.8354 |
| QED | 0.842 |
| Synth | 4.586 |
| Natural Product Likeliness | 1.331 |
| NR-PPAR-gamma | 0.002 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.781 |
| Pgp-sub | 0.002 |
| HIA | 0.003 |
| CACO-2 | -4.765 |
| MDCK | 0.0000151 |
| BBB | 0.974 |
| PPB | 0.435962 |
| VDSS | 2.044 |
| FU | 0.587136 |
| CYP1A2-inh | 0.388 |
| CYP1A2-sub | 0.861 |
| CYP2c19-inh | 0.213 |
| CYP2c19-sub | 0.952 |
| CYP2c9-inh | 0.069 |
| CYP2c9-sub | 0.486 |
| CYP2d6-inh | 0.874 |
| CYP2d6-sub | 0.888 |
| CYP3a4-inh | 0.672 |
| CYP3a4-sub | 0.893 |
| CL | 11.687 |
| T12 | 0.273 |
| hERG | 0.252 |
| Ames | 0.018 |
| ROA | 0.805 |
| SkinSen | 0.13 |
| Carcinogencity | 0.133 |
| EI | 0.015 |
| Respiratory | 0.974 |
| NR-Aromatase | 0.003 |
| Antiviral | No |
| Prediction | 0.629475 |